Search Results
Your search for world matches 4350 pages
Showing 2251 - 2300KEYNOTE-181: Pembrolizumab vs Chemotherapy in Second-Line Treatment of Advanced Esophageal Cancer
IN THE GLOBAL phase III KEYNOTE-181 trial, pembrolizumab as second-line therapy for advanced esophageal cancer did not improve overall survival in the whole population, vs chemotherapy, but did improve survival for patients with strong expression of programmed cell death ligand 1 (PD-L1),...
Trends in Neoadjuvant Therapy for Resectable Pancreatic Cancer
SEVERAL STUDIES at the 2019 Gastrointestinal Cancers Symposium evaluated the benefits of neoadjuvant treatment in patients with pancreatic cancer—and in patients deemed fully resectable, not just “borderline” resectable.1-3 Although the standard of care for resectable pancreatic ductal...
FDA Expands Palbociclib Indication in HR-Positive, HER2-Negative Breast Cancer to Include Male Patients
Today, the U.S. Food and Drug Administration (FDA) extended the indication of palbociclib (Ibrance) capsules in combination with specific endocrine therapies for hormone receptor (HR)–positive, HER2-negative advanced or metastatic breast cancer to include male patients. “Today, we are...
ASCO Multidisciplinary Cancer Management Course in Azerbaijan: A Well-Attended Success
The National Center of Oncology (NCO) in Azerbaijan partnered with ASCO, the American Society for Clinical Pathology (ASCP), and the Oncology Nursing Society (ONS) to conduct a highly successful Multidisciplinary Cancer Management Course (MCMC) in September 2018 in Baku, Azerbaijan. The conference...
Genomic Testing Associated With Lower Health-Care Costs in Patients With High-Risk Breast Cancer
New research published by Dinan et al in JNCCN—Journal of the National Comprehensive Cancer Network provides evidence that genomic recurrence score testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast...
Immunotherapy Directed Against Precancerous Skin Lesions May Prevent Squamous Cell Carcinoma
A treatment previously shown to treat the precancerous skin lesions called actinic keratosis now appears to also reduce the chance that these pretreated lesions will develop into squamous cell carcinoma. In a report published by Rosenberg et al in JCI Insight, researchers found that treatment with...
Use Technology and Appreciate the Importance of Partners
Most oncologists are comfortable treating lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients with cancer, according to a survey of 149 oncologists from 45 National Cancer Institute–designated Comprehensive Cancer Centers, but not as confident in their knowledge of the...
WebMD Recognizes Seven Cancer Innovators With Its Health Heroes Award
On January 15, 2019, WebMD, an online and print health-care resource for consumers, presented its 2018 Health Heroes Award in New York City to 7 people who are making a difference in oncology care. The honorees include Karen M. Winkfield, MD, PhD, Associate Professor of Radiation Oncology at Wake...
ASCO President-Elect Howard A. Burris III, MD, FACP, FASCO, Gained Leadership Skills From His Experience at West Point
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. In this installment of Living a Full Life, guest editor Jame Abraham, MD, spoke with Howard A. “Skip” Burris III, MD, FACP,...
Matthew J. Loscalzo, LCSW, on The Effects of Gender on Patients’ Coping Strategies and Stress Management
Matthew J. Loscalzo, LCSW, of the City of Hope, discusses the ways in which a person’s gender influences how he or she reacts to and copes with a cancer diagnosis and treatment.
CAR T-Cell Therapy for DLBCL: At the Crossroads of Hype and Reality
In the 20-plus years I have spent in hematologic oncology, I have been fortunate to have a ringside seat to watch “game-changing” advances come into our field—all-trans retinoic acid for acute promyelocytic leukemia, tyrosine kinase inhibitors starting with imatinib for chronic myeloid leukemia,...
FDA Pipeline: Assay Approval, Breakthrough Designations for AI Technology and CLL, and More
In the past week, the U.S. Food and Drug Administration (FDA) approved a companion diagnostic assay, granted Breakthrough Device and Breakthrough Therapy designations, and extended the review period of a proposed treatment. The agency also published four draft guidances and one final guidance...
Activity of Cabozantinib in Advanced Non–Clear Cell Renal Cell Carcinoma
In a retrospective cohort study reported in The Lancet Oncology, Chanzá et al found evidence of activity of cabozantinib in advanced non–clear cell renal carcinoma. Cabozantinib is approved in metastatic renal cell carcinoma on the basis of studies in clear cell histology. As noted by ...
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation proudly recognize the winners of ASCO’s Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. ASCO...
Global Incidence of Undiagnosed Pediatric Cancers
Nearly half of all childhood cancers are not being diagnosed globally, according to a new modeling study published by Ward et al in The Lancet Oncology. “Our model suggests that nearly one in two children with cancer are never diagnosed and may die untreated,” said lead...
Omega-3 Fatty Acids
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, explore the use of omega-3 fatty acids, which have...
A Peaceful Transformation: The Origin of the Frederick National Laboratory
JUST 2 MONTHS before Congress passed what to this day is America’s most sweeping anticancer legislation, President Richard Nixon came to Fort Detrick in Frederick, Maryland, to declare his administration’s historic commitment to the fight. “I have come here today for the purpose of making an...
Although Evidence Is Clear That Lung Cancer Screening Saves Lives, Adoption Rates Remain Low
The findings of the National Lung Screening Trial (NLST), reported in 2011, revealed that participants who received low-dose helical computed tomography (CT) scans had a 20% lower risk of dying of lung cancer than participants who received standard chest x-rays. Despite these results,...
2019 AAD: Disadvantages and Potential Improvements of Artificial Intelligence in Skin Cancer Detection
While artificial intelligence (AI) systems for skin cancer detection have shown promise in research settings, there is still a lot of work to be done before the technology is appropriate for real-world use. This was the topic of a scientific session at the 2019 American Academy of Dermatology (AAD) ...
Eliminating the Taboo of Cancer
All homes and all families have or have had their own cancer experiences. Speaking about it dissolves the taboo and allows for earlier diagnosis, less discrimination, increased awareness, and higher commitment by authorities. It also helps those struggling with the disease feel like part of a...
ASCO University Course Focuses on Fertility Preservation
Cancer can affect fertility in both men and women from adolescence through adulthood. Fertility preservation is often not addressed early enough during cancer treatment, but it should be a standard component of comprehensive care for prepubertal and reproductive-age patients. ASCO University offers ...
Who I Am and What I Will Do
I am a radiation oncologist from Zambia, where we only have one cancer center offering radiotherapy—and I will beat cancer. This bold statement often evokes a look of surprise. However, if the conversation is allowed to go on, I’ll say cancer is beatable even where resources are thin. I am...
Otis W. Brawley, MD, Joins Faculty of Johns Hopkins Kimmel Cancer Center
Otis W. Brawley, MD, an authority on cancer screening and prevention who served as Chief Medical and Scientific Officer for the American Cancer Society and Director of the Georgia Cancer Center at Grady Memorial Hospital in Atlanta, has been named a Bloomberg Distinguished Professor at Johns...
TAT 2019: Trends in Distribution of Cancer Type in Phase I Trials
The proportion of early-stage drug trials tackling the most common tumor types has declined sharply since the early 1990s, as less common cancers receive increasing attention in trials, according to new research presented by Sato et al at the TAT 2019–International Congress on Targeted...
Relapse Risk and Survival With Contemporary Therapy in Young Patients With Hodgkin Lymphoma
In a Nordic Lymphoma Epidemiology Group study reported in the Journal of Clinical Oncology, Biccler et al found that relapse risk and loss in expectation of lifetime were low in young patients receiving contemporary therapy for classical Hodgkin lymphoma. Outcomes were particularly good among...
AACR 2019: Does Treatment With Abiraterone Acetate Benefit Patients With Advanced Prostate Cancer and Preexisting Cardiovascular Disease?
Patients with advanced prostate cancer who had preexisting cardiovascular disease had a higher risk of mortality in the 6 months after starting abiraterone acetate treatment compared with those who had no preexisting cardiovascular disease, according to data presented by Lu-Yao et al at a presscast ...
Decline in Rates for HPV16/18-Positive Cervical Precancers Since Introduction of the HPV Vaccine
According to the World Health Organization, approximately 70% of cervical cancers worldwide are caused by the human papillomavirus (HPV) types 16 and 18. In 2006, the HPV vaccine was introduced in the United States to prevent HPV-associated morbidity and mortality. A study analyzing data on the...
Update on FDA-Approved CAR T-Cell Products
AXICABTAGENE CILOLEUCEL (also known as CAR19) is an anti-CD19 chimeric antigen receptor (CAR) T-cell product approved by U.S. Food and Drug Administration to treat selected hematologic malignancies.1 To appreciate the clinical trial findings summarized here, from selected abstracts presented at the ...
Emerging Role for Neoadjuvant Treatment of Resectable Pancreatic Cancer
SEVERAL STUDIES presented at the 2019 Gastrointestinal Cancers Symposium evaluated the benefits of neoadjuvant treatment in patients with pancreatic cancer—and in patients deemed fully resectable, not just “borderline” resectable.1-3 Although the standard of care for resectable pancreatic ductal...
Expert Point of View: Mark Crowther, MD, MSc, FRCPC
Session moderator Mark Crowther, MD, MSc, FRCPC, Professor of Clinical Epidemiology and Biostatistics and Leo Pharma Chair in Thromboembolism Research at McMaster University, in Ontario, Canada, said that the results of the PAUSE study provide the most definitive evidence to date regarding how...
Expert Point of View: Mark Crowther, MD, MSc, FRCPC
Moderator of the session, Mark Crowther, MD, MSc, FRCPC, Professor of Clinical Epidemiology and Biostatistics, Leo Pharma Chair in Thromboembolism Research at McMaster University, in Ontario, Canada, said that the CASSINI study represents a major advance in the management and prevention of a very...
Physician Wellness: Time to Heal the Healer
Physician wellness is emblazoned upfront in the news with attention-seeking headlines on a daily basis. The fact that one or two physicians commit suicide every day in this country sometimes elicits more of a sympathetic acknowledgment than a committed call to address it. Moreover, these sobering...
Artificial Intelligence and the Brave New World of Cancer Diagnostics
A study published in Nature Medicine found that an artificial intelligence program could distinguish between the histologic diagnosis of adenocarcinoma and squamous cell carcinoma.1 Experienced pathologists often struggle to differentiate these tumor types without confirmatory tests. The artificial ...
Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Results From the NIVOREN GETUG-AFU 26 Study on Nivolumab
Laurence Albiges, MD, PhD, of Gustave Roussy, discusses findings on the safety and efficacy of nivolumab used in a “real world” prospective study on metastatic renal cell carcinoma (mRCC). This research was conducted after nivolumab was approved for the treatment of mRCC following failure of one or ...
Encourage Lung Cancer Screening to Prevent Early Deaths
Discussions of benefits and harms from screening of high-risk populations for lung cancer have missed the point. The National Lung Screening Trial (NLST) showed an early and statistically significant major benefit in all-cause mortality from computed tomography (CT) screening.1 Those referred for...
NCCN Guidelines Exceed 10 Million Downloads in 2018
THE NATIONAL Comprehensive Cancer Network® (NCCN®) announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) were downloaded more than 10 million times in 2018, marking a 26% increase over downloads in 2017. The NCCN Guidelines provide up-to-date recommendations for...
FDA Pipeline: Treatments for Tenosynovial Giant Cell Tumor and Pancreatic Cancer, Plus a Statement on Breast Implant–Associated Lymphoma
The U.S. Food and Drug Administration (FDA) recently granted the following designations and applications and also issued a statement: Priority Review for Pexidartinib in Tenosynovial Giant Cell Tumor The FDA has accepted a new drug application (NDA) and granted Priority Review for pexidartinib...
Real-World Treatment Impact of Newer Agents on Survival of Patients With Metastatic Melanoma
The approval of several new agents for metastatic melanoma in the past several years has led to changes in how the disease is treated and managed. Treatments such as the programmed cell death protein 1 (PD-1) inhibitors pembrolizumab, ipilimumab, and nivolumab; BRAF inhibitors; and MEK inhibitors...
Leave a Legacy of Hope
By including a planned gift to ASCO’s Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for patients with cancer years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and...
World Cancer Day 2019: Emphasis on Early Detection
World Cancer Day 2019—February 4—highlights the need for urgent action to increase early-stage cancer detection, screening, and diagnosis to significantly improve patients’ chances of survival. Taking place with the theme of “I Am and I Will,” World Cancer...
Essential Elements of an Effective Clinical Trials System: Business and Mission
Clinical trials aimed to improve health and quality of life are the cornerstone of progress in medicine. Support comes from academic medical centers, philanthropy, the National Institutes of Health (NIH), industry, or combinations thereof. Clinical trials need to be hypothesis-driven and address...
KEYNOTE-181: Pembrolizumab vs Chemotherapy in Second-Line Treatment of Advanced Esophageal Cancer
In the global phase III KEYNOTE-181 trial, pembrolizumab as second-line therapy for advanced esophageal cancer did not improve overall survival in the whole population, vs chemotherapy, but did improve survival for patients with strong expression of programmed cell death ligand 1 (PD-L1),...
How Effective Is Talimogene Laherparepvec Injection in Metastatic Melanoma?
Injection of a genetically modified virus that induces the body’s own immune cells to attack metastatic melanoma effectively treated almost 40% of patients with tumors that could not be surgically removed, according to findings published by Louie et al in the Journal of the American...
Effectiveness of EsophaCap Tool in the Diagnosis of Barrett’s Esophagus
Barrett’s esophagus is the only known precursor of esophageal adenocarcinoma. Although endoscopy and biopsy are standard methods for diagnosing Barrett’s esophagus, their high cost and risk limit their use as a screening modality. Researchers sought to develop a screening method based...
2018 Update of WHO-EORTC Classification of Primary Cutaneous Lymphomas
As reported by Willemze and colleagues in Blood, the World Health Organization (WHO) and the European Organisation for Research and Treatment of Cancer (EORTC) have released a 2018 update of their classification of primary cutaneous lymphomas. As noted by the authors, “Primary cutaneous...
Oncology Pioneer V. Shanta, MD, Has Long Championed Access to Quality Cancer Care
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed V. Shanta, MD, an internationally renowned oncologist and Chairperson of the Cancer Institute in Adyar, Chennai, India. Dr. Shanta has been with the Institute since 1955, holding several positions...
Hastening the Development of Novel Therapies for Peripheral T-Cell Lymphomas
Peripheral T-cell lymphomas (PTCLs) make up a small fraction of all non-Hodgkin lymphomas—just 15%—in the United States.1 Although rare in the United States, the incidence of PTCL is common across Asia, the Caribbean, and sub-Saharan Africa. Although the reason for such global variation in PTCL is...
Community Oncology Alliance Elects New Officers and Board Members
THE COMMUNITY Oncology Alliance (COA) recently announced that Michael Diaz, MD, a practicing medical oncologist at Florida Cancer Specialists & Research Institute, has been elected President of COA. His 1-year term began on January 1, 2019. In addition, Kashyap Patel, MD, a practicing...
Challenge Moving Forward in Breast Cancer Treatment: To Show That New Approaches Change Outcomes
ADVANCES IN treating breast cancer over the past 20 years have brought us to the point where treatment can be confidently de-escalated for some patients, and immunotherapy and precision decision-making may change the way breast cancer is treated for others, William Gradishar MD, FASCO, told the...
Preventing Locoregional Recurrence of Breast Cancer Should Not Deter Efforts to Decelerate Therapy
“SURGEONS AND radiation oncologists are obsessed with locoregional recurrence of breast cancer,” Monica Morrow, MD, FASCO, remarked at the 2018 Lynn Sage Breast Cancer Symposium, Chicago. Working to prevent locoregional recurrence, “even if it may not be the major threat to mortality, is...
